COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
申请人:Johansen Lisa M.
公开号:US20100009970A1
公开(公告)日:2010-01-14
The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.
Structural and functional highlights of methionine aminopeptidase 2 from Leishmania donovani
作者:Saleem Yousuf Bhat、Arijit Dey、Insaf A. Qureshi
DOI:10.1016/j.ijbiomac.2018.04.090
日期:2018.8
a Ki value of 0.86 μM. Further, structural studies with circulardichroism (CD) showed an increase in the α-helical and β-sheet contents and a decrease in random coils in LdMAP2 upon interactions with both bestatin and fluorogenic substrates. Finally, structural studies pointed out key differences in the structure of LdMAP2 and HsMAP2 and their interactions with inhibitor bestatin, Ala-AMC, Leu-AMC
蛋氨酸氨基肽酶2(MAP2)是多形利什曼原虫凋亡的主要调节剂,也是新型抗疟原虫药的设计和合成的潜在候选者。将LdMAP2基因克隆到pET28a(+)-SUMO载体中,在大肠杆菌中表达,然后通过色谱法纯化。发现它是一种单体,并且由于其对合成底物的活性具有二价金属离子,其中Co(II),Mg(II),Mn(II)和Ni(II)是主要的活化剂。此外,Ca(II)显示出最紧密的结合,K m值为124.7±9.2μM,而Co(II)被证明是最有效的催化方法,k cat值为128.1±4 min -1。发现天然存在的氨基肽酶B抑制剂Bestatin是具有K i的LdMAP2的有效抑制剂。值为0.86μM。此外,具有圆二色性(CD)的结构研究表明,与Bestatin和荧光底物相互作用时,LdMAP2中的α-螺旋和β-折叠含量增加,而无规卷曲减少。最后,结构研究指出了LdMAP2和HsMAP2在结构上的关
Mutations of key substrate binding residues of leishmanial peptidase T alter its functional and structural dynamics
作者:Saleem Yousuf Bhat、Insaf Ahmed Qureshi
DOI:10.1016/j.bbagen.2019.129465
日期:2020.1
carries broad substrate specificity with best cleavage preference for peptides carrying alanine at the P1 position. Peptidomimetics amastatin and actinonin occupied S1 pocket by competing with the substrate for binding to activesite and inhibited PepT potently, while arphamenine A and bestatin were less effective inhibitors. We further show that the mutation of conserved substratebinding residues (T364
Human laeverin/aminopeptidase Q (APQ) is a novel member of the M1 family of zinc aminopeptidases and is specifically expressed on the cell surface of extravillous trophoblasts. In this study, we examined the significance of Gln-238 of laeverin/APQ, a putative S1 site residue, by site-directed mutagenesis for its enzymatic activity and substrate specificity. Replacement of Gln-238 with Ala caused a significant change in substrate specificity rather than a decrease in enzymatic activity. These results indicate that Gln-238 is important for the substrate specificity of laeverin/APQ. In addition, our data suggest that direct electrostatic interaction between substrate and S1 site of the enzyme is not involved in the mutant enzyme's preference for basic amino acids.
Method of measuring the number of cells of microorganisms
申请人:AJINOMOTO CO., INC.
公开号:EP0122148A1
公开(公告)日:1984-10-17
A method of measuring the number of microorganism cells in a sample which comprises preparing a solution or suspension containing a sample of a medicine, food, drink, cosmetic or water, adding to said solution or suspension a 7-amino-4-methyl-coumarin derivative represented by formula (1):
wherein R is an alkyl group, an allyl group, an aralkyl group, or a heterocyclic group, or R-CO- is an amino acid or peptide residue, said derivative not inhibiting the hydrolysis of the amine bond of formula (1) by microorganism hydrolases contained in the samples; and measuring the fluorescence of 7-amino-4--methyl-coumarin released by the microorganism hydrolases.
一种测量样品中微生物细胞数量的方法,包括制备含有药物、食品、饮料、化妆品或水样品的溶液或悬浮液,向所述溶液或悬浮液中加入由式(1)代表的7-氨基-4-甲基香豆素衍生物:
其中 R 是烷基、烯丙基、芳烷基或杂环基,或 R-CO- 是氨基酸或肽残基,所述衍生物不抑制样品中含有的微生物水解酶水解式(1)的胺键;以及测量微生物水解酶释放的 7-氨基-4-甲基香豆素的荧光。